




The relative strengths and weaknesses of Syros Pharmaceuticals Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Syros Pharmaceuticals Inc compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 85% points. The greatest weakness of Syros Pharmaceuticals Inc is the variable Research and Development, reducing the Economic Capital Ratio by 25% points.

The company's Economic Capital Ratio, given in the ranking table, is 304%, being 55% points above the market average of 250%.

Input Variable	Value in 1000 USD
Assets, Current	101,734
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	19,529
Liabilities, Non-Current	0
Other Assets	1,171
Other Compr. Net Income	39
Other Expenses	0
Other Liabilities	0
Other Net Income	2,017
Other Revenues	2,050
Property and Equipment	3,861
Research and Development	50,182
Selling, General and Administrative Expense	16,164

Output Variable	Value in 1000 USD
Assets	106,766
Liabilities	19,529
Expenses	66,346
Revenues	2,050
Stockholders Equity	87,237
Net Income	-62,279
Comprehensive Net Income	-62,260
BaseVar	98,374
ECR before LimitedLiability	203%
Economic Capital Ratio	304%